1 / 28

¿Qué sabemos del tratamiento de la insuficiencia cardiaca por disfunción diastólica? Dr. Ruiz Laiglesia 15 de noviembre

¿Qué sabemos del tratamiento de la insuficiencia cardiaca por disfunción diastólica? Dr. Ruiz Laiglesia 15 de noviembre de 2006. Trends in Prevalence and Outcome of Heart. Failure with Preserved Ejection Fraction. Owen TE. N Engl J. Med 2006; 355: 251-9. 54%. 38%.

rayya
Download Presentation

¿Qué sabemos del tratamiento de la insuficiencia cardiaca por disfunción diastólica? Dr. Ruiz Laiglesia 15 de noviembre

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ¿Qué sabemos del tratamiento de la insuficiencia cardiaca por disfunción diastólica? Dr. Ruiz Laiglesia 15 de noviembre de 2006

  2. Trends in Prevalence and Outcome of Heart. Failure with Preserved Ejection Fraction. Owen TE. N Engl J. Med 2006; 355: 251-9

  3. 54% 38% Trends in Prevalence and Outcome of Heart. Failure with Preserved Ejection Fraction. Owen TE. N Engl J. Med 2006; 355: 251-9

  4. 29% 32% 65% 68% Trends in Prevalence and Outcome of Heart. Failure with Preserved Ejection Fraction. Owen TE. N Engl J. Med 2006; 355: 251-9

  5. Trends in Prevalence and Outcome of Heart. Failure with Preserved Ejection Fraction. Owen TE. N Engl J. Med 2006; 355: 251-9

  6. Trends in heart failure incidence and survival in a community-based population. Roger VI eta l. JAMA 2004; 292: 344-50

  7. Diastolic heart failure. The condition exits and needs to be recognised, prevented, and treated. Vasan RS. BMJ 2003; 327: 1181-2

  8. Digoxina The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Eng J Med 1997; 336: 525-33.

  9. Digoxina The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Eng J Med 1997; 336: 525-33.

  10. IECAs Perindopril The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Cleland JGF. Eur Heart J 2006; 27: 2338-45

  11. THE LANCET ARAII Candesartan Ibesartan Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARN-PreservedTrial. Yusuf S et al. Lancet 2003: 362: 777-81

  12. Betabloqueantes Nevibolol Randomized trial to determine the effect if nevibolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Flather M et al. Eur Heart J 2006; 26: 215-25.

  13. Betabloqueantes Propanolol Propranolol Versus No Propranolol on Total Plus Nonfatal Myocardial Infarction n Older With Prior Myocardial Infarction, Congestive Failure, and Left Ventricular Ejection fraction Treated With Diuretics Plus Angiotensin- Converting Enzyme Inhibitors. Aronow WS et al. Am J Cardiol 1997; 80: 207-9

  14. Effect of verapamil in elerly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Hung MJ et al. Int J Clin Prac 2002; 56: 57 - 62 Spironolactone improves diastolic function in the elderly. Roongsritong C et al. Clin Cardiol 2005; 28: 484 – 7 Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study. Juurlink DN. N Eng J Med 2004; 315: 543 – 551. Fármacos con estudios poco controlados

  15. Fármacos con estudios poco controlados Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study. Juurlink DN. N Eng J Med 2004; 315: 543 – 551.

  16. ACC/AHA 2005 guidelines uptodate for the diagnosis and management of chronic heart failure inthe adult. Circulation 2005; 112: 1825-1852. Guías de práctica clínica sobre el diagnóstico y tratamiento de la insuficiencia cardiaca crónica. Versión resumida. Actualización 2005. Rev Esp Cardiol 2005; 58: 1062-92.

  17. Médico Alagebrium (ALT-711) The Effect of Alagebrium Chloride (ALT-711), a Novel Glucose Cross-Link Breaker, in the Treatment of Elderly Patients With Diastolic Heart Failure. Littel WC et al. J Card Fail 2005; 11: 191-5

  18. Contracción y relajación miofibrilar

  19. SERCA2a Contracción y relajación miofibrilar

  20. MCC-135, 5-methyl-2-(1-piperazinyl) benzenesulfonic acid monohydrate Médico • Lusitropic Effect of MCC-135 Is Associated with Improvement of Sarcoplasmic Reticulum Function in Ventricular Muscles of Rats with Diabetic Cardiomyopathy. Naoya Satoh et al. J Pharmacol Exp Ther 2001; 298: 1161-6 • Patients with Acute Myocardial Infarction: Rationale and Design of the Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI (EVOLVE) Study • Ik-Kyung Jang et al. Journal of Thrombosis and Thrombolysis 2005; 20: 147–153.

  21. SERCA2a Sobreexpresión de la SERCA2a Terapia génica Adenoviral gene transfer of SERCA2a improves left-ventricular functión in aortic-banded rats in transition to heart failure. Miyamoto MI. Proc Natl Acad Sci USA 2000; 97: 793-8

  22. SERCA2a Sobreexpresión del fosfofalamban fosforilado Terapia génica Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. Iwanaga Y. J Clin Invest 2004; 113: 727-36.

  23. Dispositivos • LENVRAN VAD • Dispositivos de asistencia pasiva diastólica

  24. Objetivos del tratamiento Mejorar los síntomas Aumentar la capacidad funcional Reducir los ingresos hospitalarios Disminuir la mortalidad Tratamiento Control de la presión arterial Control de la frecuencia ventricular si ACxFA Utilización de diuréticos si congestión pulmonar o edemas Revascularización si isquemia miocárdica sintomática Utilización de IECAs, ARA II, β bloqueantes Utilizar la digoxina para mantener el ritmo sinusal o controlar la frecuencia cardiaca. Resumen ¿Qué sabemos del tratamiento de la insuficiencia cardiaca por disfunción diastólica?

More Related